PELLEPHARM

Phyton Biotech Announces the Successful Establishment of Plant Cell Lines to Source Key Building Block for Treatment of Rare Dermatologic Conditions

Retrieved on: 
Monday, January 11, 2021
Alternative medicine, Health, Research, Pharmaceutical, Science, Biotechnology, Organic compounds, Life sciences, Biotechnology, Biology, Spiro compounds, Plant toxins, Secondary alcohols, Biological engineering, Cyclopamine, Cryopreservation, Cell culture, Bioreactor, Phyton Biotech, PellePharm, Patidegib

Phyton Biotech today announced that it has established high-yielding plant cell lines of Veratum californicum, the source of cyclopamine, a key raw material for PellePharms patedigib topical gel, an investigational treatment to be used for rare dermatologic conditions.

Key Points: 
  • Phyton Biotech today announced that it has established high-yielding plant cell lines of Veratum californicum, the source of cyclopamine, a key raw material for PellePharms patedigib topical gel, an investigational treatment to be used for rare dermatologic conditions.
  • Through Phytons proprietary Plant Cell Fermentation (PCF) technology, researchers successfully developed high-yielding plant cell lines of V. californicum and established protocols for cryopreservation, allowing for stable long-term storage of cell lines in liquid nitrogen.
  • In addition, Phyton Biotech demonstrated its ability to express cyclopamine directly from V. californicum plant cell cultures via PCF and also showed that cyclopamine can be expressed efficiently in a standard bioreactor environment.
  • Further development and full scale-up to a commercially viable process is anticipated in the next project phase.

PellePharm to Highlight Clinical Programs at the 29th Congress of the European Academy of Dermatology and Venereology

Retrieved on: 
Thursday, October 29, 2020
Oncology, Health, Genetics, Clinical trials, Pharmaceutical, Biotechnology, Syndromes, Clinical medicine, Organ systems, Gorlin, Nevoid basal-cell carcinoma syndrome, Patidegib, Gorlin Syndrome, High Frequency Basal Cell Carcinoma (HF-BCC), PellePharm, BridgeBio Pharma

The presentations will be made during the 29th Congress of the European Academy of Dermatology and Venereology (EADV), to be held virtually October 29 31, 2020.

Key Points: 
  • The presentations will be made during the 29th Congress of the European Academy of Dermatology and Venereology (EADV), to be held virtually October 29 31, 2020.
  • Our research continues to generate compelling evidence that supports patidegib as a clinical candidate and validates our approach in hedgehog inhibition.
  • Details for the poster presentations at EADV Virtual are as follows:
    We are encouraged by the continuing promise that patidegib is demonstrating in the clinic.
  • Patidegib topical gel has shown early promise in a Phase 2 clinical study for the mitigation of BCC tumors in Gorlin syndrome.

PellePharm Completes Enrollment of Pivotal Phase 3 Clinical Trial of Patidegib Topical Gel in Patients with Gorlin Syndrome

Retrieved on: 
Monday, December 2, 2019
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Health, Syndromes, Pharmacology, Nevoid basal-cell carcinoma syndrome, Gorlin, Topical medication, Hydrosal Gel, Patidegib, Gorlin Syndrome, High Frequency Basal Cell Carcinoma (HF-BCC), PellePharm, LEO Pharma, BridgeBio Pharma

PellePharm, Inc., a BridgeBio Pharma, Inc. (Nasdaq: BBIO) company, today announced the completion of enrollment for its pivotal Phase 3 clinical trial of Patidegib Topical Gel 2% vs. vehicle gel in patients with Gorlin Syndrome.

Key Points: 
  • PellePharm, Inc., a BridgeBio Pharma, Inc. (Nasdaq: BBIO) company, today announced the completion of enrollment for its pivotal Phase 3 clinical trial of Patidegib Topical Gel 2% vs. vehicle gel in patients with Gorlin Syndrome.
  • The randomized, double-blind, vehicle-controlled Phase 3 trial is evaluating the safety and efficacy of Patidegib Topical Gel 2% applied, twice daily to the face over 12 months vs. vehicle gel.
  • LEO Pharma is providing resources to PellePharm to fund, amongst other activities, its Phase 3 trial of Patidegib Topical Gel 2% in patients with Gorlin Syndrome under the terms of the agreement.
  • Patidegib Topical Gel has shown early promise in a Phase 2 clinical study for the mitigation of BCC tumors in Gorlin Syndrome.